Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
442.00    -4.00 (-0.90%)
Bid:
442.00
Ask:
446.50
Spread: 4.50 (1.018%)
Market Cap: £217.38m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Operational and Trading Update

5 Nov 2020 07:00

RNS Number : 2892E
Zotefoams PLC
05 November 2020
 

Zotefoams plc

("Zotefoams" or "Group")

 

Operational and Trading Update

 

5 November 2020 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the third quarter, ended 30 September 2020.

 

Zotefoams is pleased to report a record third-quarter sales performance, with revenues approximately 22% ahead of Q3 2019. This reflected very strong contributions, as expected, from both personal protective equipment ("PPE") and footwear products. While the large PPE programme runs down through the latter part of 2020, the strong momentum in footwear and T-FIT® insulation products, together with early indications of demand recovery in a number of our markets, supports the Board's continued expectation of strong year-on-year sales growth in Q4. Using current foreign exchange rates and subject to there being no material disruption to the business, the Board expects full-year revenues and underlying profit before tax to be in line with market expectations.

 

Operating cash performance has continued to be solid, with net debt at 30 September 2020 of £36m, in line with management expectations. The strong trading momentum through the second half, together with the effective cash management actions taken, have left the Group in a resilient financial position. The commissioning of our new foam manufacturing site in Poland is in progress, with first product expected to be shipped to customers in early Q1 2021. In addition, the commissioning of the pilot line for our ReZorce® mono-material barrier packaging technology is expected to begin in December with availability for external trials also in Q1 2021.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"2020 has been a difficult year for many businesses. I am pleased Zotefoams' results are demonstrating the wide applicability of our products and the resilience and flexibility of our people. Our current performance allows us to look beyond the current economic circumstances and maintain our strategy of investing in the current year to support the delivery of longer-term growth."

 

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

 

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam manufacturing site, in Poland, is planned to begin operations in 2020.

 

www.zotefoams.com 

 

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFLRLRLSIII
Date   Source Headline
14th May 20203:15 pmRNSDirector/PDMR Shareholding
6th May 20207:00 amRNS2019 Annual Report and Notice of the 2020 AGM
28th Apr 20204:39 pmRNSDisclosure of rights attached to equity shares
22nd Apr 20203:51 pmRNSDirector/PDMR Shareholding
16th Apr 202012:39 pmRNSDirector/PDMR Shareholding
14th Apr 20202:41 pmRNSDirector/PDMR Shareholding
8th Apr 20204:19 pmRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSPreliminary Results
1st Apr 20207:00 amRNSNotice of Results
31st Mar 202012:07 pmRNSSecond Price Monitoring Extn
31st Mar 202012:02 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNS2019 Summary, COVID-19 and Current Trading Update
23rd Mar 20207:00 amRNSDelayed Preliminary Results
19th Mar 20208:40 amRNSDirectorate Change
17th Mar 20209:49 amRNSHolding(s) in Company
12th Mar 20204:11 pmRNSDirector/PDMR Shareholding
10th Mar 20204:30 pmRNSNotice of Results
27th Feb 20203:00 pmRNSDirector Declaration
12th Feb 20209:24 amRNSDirector/PDMR Shareholding
21st Jan 20207:00 amRNSYear-End Trading Update
16th Jan 20203:33 pmRNSHolding(s) in Company
13th Jan 20204:21 pmRNSDirector/PDMR Shareholding
27th Dec 20199:03 amRNSHolding(s) in Company
17th Dec 20199:34 amRNSDirector/PDMR Shareholding
13th Dec 20198:41 amRNSHolding(s) in Company
3rd Dec 20197:00 amRNSHolding(s) in Company
26th Nov 201910:39 amRNSHolding(s) in Company
13th Nov 20193:09 pmRNSDirector/PDMR Shareholding
15th Oct 20192:50 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
15th Oct 20199:48 amRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
15th Oct 20197:00 amRNSDirector/PDMR Shareholding
11th Oct 20194:31 pmRNSHolding(s) in Company
9th Oct 20192:37 pmRNSDirector/PDMR Shareholding
9th Oct 20197:00 amRNSNew technology for recyclable packaging
8th Oct 20197:00 amRNSAppointment of Joint Broker
3rd Oct 20197:00 amRNSTrading Update
1st Oct 201911:47 amRNSDirector Declaration
16th Sep 20193:39 pmRNSDirector/PDMR Shareholding
6th Sep 201912:07 pmRNSSecond Price Monitoring Extn
6th Sep 201912:02 pmRNSPrice Monitoring Extension
27th Aug 201912:07 pmRNSSecond Price Monitoring Extn
27th Aug 201912:02 pmRNSPrice Monitoring Extension
21st Aug 201912:07 pmRNSSecond Price Monitoring Extn
21st Aug 201912:02 pmRNSPrice Monitoring Extension
13th Aug 20193:26 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results
15th Jul 20194:31 pmRNSDirector/PDMR Shareholding
12th Jul 20193:51 pmRNSDirector/PDMR Shareholding
10th Jul 20194:22 pmRNSHolding(s) in Company
9th Jul 20197:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.